New asthma drug aims to stop severe attacks
NCT ID NCT07098403
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This Phase 3 trial tests an experimental drug called SHR-1905 in 408 adults with severe asthma that is not well controlled by current treatments. Participants receive either the drug or a placebo injection. The main goal is to see if the drug reduces the number of asthma attacks over a year. Researchers will also check lung function and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, 510830, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1905 injection
What this could lead to
If it works, this could provide a new treatment option to better control severe asthma and reduce sudden attacks.
What could go wrong
This is an early Phase 3 trial, so results are not yet proven. The drug may not work better than placebo, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.